|
1 Indications And Usage Genvoya Is Indicated As A Complete Regimen For The Treatment Of Hiv-1 Infection In Adults And Pediatric Patients Weighing At Least 25 Kg Who Have No Antiretroviral Treatment History Or To Replace The Current Antiretroviral Regimen In Those Who Are Virologically-Suppressed (hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen For At Least 6 Months With No History Of Treatment Failure And No Known Substitutions Associated With Resistance To The Individual Components Of Genvoya [see Clinical Studies (14) ]. Genvoya Is A Four-Drug Combination Of Elvitegravir, An Hiv-1 Integrase Strand Transfer Inhibitor (insti), Cobicistat, A Cyp3a Inhibitor, And Emtricitabine And Tenofovir Alafenamide (taf), Both Hiv-1 Nucleoside Analog Reverse Transcriptase Inhibitors (nrtis), And Is Indicated As A Complete Regimen For The Treatment Of Hiv-1 Infection In Adults And Pediatric Patients Weighing At Least 25 Kg Who Have No Antiretroviral Treatment History Or To Replace The Current Antiretroviral Regimen In Those Who Are Virologically-Suppressed (hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen For At Least 6 Months With No History Of Treatment Failure And No Known Substitutions Associated With Resistance To The Individual Components Of Genvoya. ( 1 )
|